secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001104659-23-001858
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris finalizes CEO and CFO employment agreements; Manion $600k base, Balthaser $444k base
--------------------------------------------------------------------------------

- Douglas Manion appointed CEO effective Jan 1, 2023 with annual base salary of $600,000 and target bonus of 55% of base.
- Kevin Balthaser appointed CFO effective Jan 1, 2023 with annual base salary of $444,000 and target bonus of 40% of base.
- Both employment agreements have initial two-year term with automatic renewal; severance includes 12-month base salary and COBRA in non-change-of-control terminations.
- Under change of control termination, Manion receives additional 6 months salary and 150% target bonus; Balthaser receives additional target bonus; both get full equity acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465923001858/0001104659-23-001858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465923001858/tm232381d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-001858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer